Valuation: Voyageur Pharmaceuticals Ltd.

Market Cap 30.56M 21.57M 18.87M 17.4M 16.1M 2.06B 31.07M 208M 81.68M 1.01B 80.97M 79.22M 3.5B P/E 2024
-5.24x
P/E 2025 -7.5x
Enterprise Value 30.33M 21.41M 18.73M 17.27M 15.98M 2.04B 30.83M 207M 81.06M 1B 80.36M 78.62M 3.48B EV / Sales 2024
-
EV / Sales 2025 2,423,581,172x
Free-Float
93.07%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer - 2019-06-30
Director of Finance/CFO - 2022-08-16
Chief Tech/Sci/R&D Officer - 2024-09-16
Director TitleAgeSince
Director/Board Member - 2017-12-05
Director/Board Member - 2019-06-30
Chairman - 2025-04-29
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+7.14% - - 21.54M
-0.30%-0.24%+53.90%+167.24% 1,084B
-1.75%-1.63%+65.56%+62.21% 634B
-1.69%-4.79%+30.39%+84.81% 447B
+0.18%-1.76%+29.04%+26.48% 330B
-6.22%-8.14%+28.87%+31.18% 295B
-1.27%-2.91%+27.42%+44.91% 285B
-0.93%-3.57%-27.74%-39.70% 218B
-1.57%-3.12%+22.25%+61.30% 199B
-1.10%+1.99%+18.23%+76.88% 169B
Average -1.48%+2.52%+27.55%+57.26% 406.65B
Weighted average by Cap. -1.39%+2.48%+38.51%+83.57%

Financials

2024 2025
Net sales - 0.01 0.01 0.01 0.01 0.01 0.79 0.01 0.08 0.03 0.39 0.03 0.03 1.34
Net income -1.71M -1.21M -1.05M -972K -899K -115M -1.74M -11.64M -4.56M -56.49M -4.52M -4.43M -196M -3.53M -2.49M -2.18M -2.01M -1.86M -238M -3.59M -24.09M -9.44M -117M -9.36M -9.16M -405M
Net Debt -113K -79.5K -69.55K -64.14K -59.34K -7.59M -115K -768K -301K -3.73M -298K -292K -12.91M -231K -163K -142K -131K -121K -15.53M -234K -1.57M -616K -7.63M -611K -598K -26.42M
Logo Voyageur Pharmaceuticals Ltd.
Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine active pharmaceutical ingredients (API) and imaging contrast agents for medical radiology. It focuses on vertically integrating the barium and iodine contrast markets. In addition, Voyageur is pursuing the development of new endo fullerene drugs. Its products include SmoothX, SmoothHD, SmoothLD, VisionHD, VisionLD and V-Gas. SmoothX (2%w/v) is a contrast medium for use in computed tomography (CT) of the gastrointestinal tract. VisionHD is a high-density (98% w/w) barium powder suspension tailored for double-contrast radiographic examination of the gastrointestinal tract, esophagus, stomach and duodenum. At the core of its operations, the Company also owns a 100% interest in the Frances Creek Project, which boasts a mineral suitable for the pharmaceutical marketplace that is intended to replace the current synthetic products with quality imaging products.
Employees
-

Annual profits - Rate of surprise